Allogene Therapeutics (ALLO) Stock Chart & Stock Price History $1.70 +0.01 (+0.59%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.29%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Allogene Therapeutics Stock Price Performance 5 Day Performance+9.68%1 Month Performance+18.06%3 Month Performance-5.56%6 Month Performance-37.50%Year-To-Date Performance-20.19%1 Year Performance-42.76% Receive ALLO Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Stock Chart for Friday, May, 2, 2025 ALLO Chart by TradingView Allogene Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/01/2025$1.68$1.69+0.60%$1.71$1.631.50 million shs$367.18 million04/30/2025$1.54$1.68+9.09%$1.70$1.516.05 million shs$365.01 million04/29/2025$1.57$1.54-1.91%$1.64$1.492.28 million shs$334.59 million04/28/2025$1.55$1.57+1.29%$1.64$1.561.61 million shs$341.11 million04/25/2025$1.57$1.55-1.27%$1.59$1.521.09 million shs$336.76 million04/24/2025$1.61$1.57-2.48%$1.62$1.541.58 million shs$341.11 million04/23/2025$1.59$1.61+1.26%$1.75$1.602.18 million shs$349.80 million04/22/2025$1.42$1.59+11.97%$1.59$1.422.32 million shs$345.45 million04/21/2025$1.45$1.42-2.07%$1.49$1.392.18 million shs$308.52 million04/18/2025$1.45$1.45$1.48$1.382.06 million shs$315.03 million Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/17/2025$1.40$1.45+3.57%$1.48$1.382.06 million shs$315.03 million04/16/2025$1.46$1.40-4.11%$1.44$1.391.27 million shs$304.17 million04/15/2025$1.43$1.46+2.10%$1.53$1.401.88 million shs$317.21 million04/14/2025$1.45$1.43-1.38%$1.49$1.382.58 million shs$310.69 million04/11/2025$1.37$1.45+5.84%$1.46$1.332.18 million shs$315.03 million04/10/2025$1.42$1.37-3.52%$1.45$1.362.57 million shs$297.65 million04/09/2025$1.36$1.42+4.41%$1.49$1.235.10 million shs$308.52 million04/09/2025$1.36$1.42+4.41%$1.49$1.235.10 million shs$308.52 million04/08/2025$1.43$1.36-4.90%$1.57$1.333.17 million shs$295.48 million04/08/2025$1.43$1.36-4.90%$1.57$1.333.17 million shs$295.48 million04/07/2025$1.44$1.43-0.69%$1.50$1.364.86 million shs$310.69 million04/04/2025$1.38$1.44+4.35%$1.46$1.323.59 million shs$312.86 million04/03/2025$1.44$1.38-4.17%$1.45$1.354.15 million shs$299.83 million04/02/2025$1.37$1.44+5.11%$1.47$1.301.97 million shs$312.86 million04/01/2025$1.46$1.37-6.16%$1.45$1.303.19 million shs$297.65 million Related Companies GPCR Stock Chart OCUL Stock Chart DYN Stock Chart ARDX Stock Chart CALT Stock Chart IOVA Stock Chart AMPH Stock Chart SNDX Stock Chart ADPT Stock Chart BGM Stock Chart Receive ALLO Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALLO) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
